Abstract
Although sinomenine (SIN) has been used to treat several inflammation-related diseases in the clinic for decades, the detailed anti-inflammatory mechanism remains elusive. Here, we present a chemoproteomic study that supports a polypharmacological mode of action for SIN to inhibit inflammation. Notably, functional validation revealed multiple new protein regulators whose knockdown could significantly affect inflammation.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / chemistry
-
Anti-Inflammatory Agents / pharmacology*
-
Cell Survival / drug effects
-
Dose-Response Relationship, Drug
-
Inflammation / chemically induced
-
Inflammation / drug therapy*
-
Lipopolysaccharides / antagonists & inhibitors
-
Lipopolysaccharides / pharmacology
-
Mice
-
Molecular Structure
-
Morphinans / chemistry
-
Morphinans / pharmacology*
-
Proteomics*
-
RAW 264.7 Cells
Substances
-
Anti-Inflammatory Agents
-
Lipopolysaccharides
-
Morphinans
-
sinomenine